The epigenetic biological age diagnostic market size has grown rapidly in recent years. It will grow from $4.96 billion in 2025 to $5.75 billion in 2026 at a compound annual growth rate (CAGR) of 16%. The growth in the historic period can be attributed to aging population growth, increasing prevalence of chronic diseases, advancement in dna methylation research, growth in academic aging research funding, early adoption of biomarker-based aging tests.
The epigenetic biological age diagnostic market size is expected to see rapid growth in the next few years. It will grow to $10.26 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to integration into preventive healthcare systems, expansion of personalized longevity medicine clinics, regulatory approval of standardized epigenetic age clocks, insurance reimbursement for biological age diagnostics, increased clinical trial usage for aging intervention therapies. Major trends in the forecast period include expansion of longevity and wellness clinics adopting biological age diagnostics, increasing regulatory standardization and validation frameworks for epigenetic aging biomarkers, rising integration of biological age testing into insurance and employer wellness programs, growth of direct-to-consumer at-home sample collection and mail-in diagnostic kits, expansion of biobanking and longitudinal cohort studies for aging research.
The increasing demand for personalized medicine is expected to propel the growth of the epigenetic biological age diagnostic market going forward. Personalized medicine refers to a medical approach that tailors disease prevention, diagnosis, and treatment based on an individual’s genetic profile, lifestyle, and environmental factors to improve clinical outcomes. The demand for personalized medicine is rising due to the increasing prevalence of chronic and complex diseases that require targeted therapies and precise diagnostic approaches. Epigenetic biological age diagnostics support personalized medicine by translating DNA methylation-based aging signals into individualized biological age profiles, enabling tailored prevention strategies, treatment selection, and lifestyle interventions for more precise and proactive healthcare. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, a significant increase compared to six approvals in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the epigenetic biological age diagnostic market.
Major companies operating in the epigenetic biological age diagnostic market are focusing on developing innovative platforms such as organ-specific biological age testing algorithms to improve precision in aging assessment, enhance early disease risk prediction, and enable personalized longevity interventions. Organ-specific biological age testing algorithms are computational models that analyze biomarkers such as DNA methylation to estimate how fast individual organs (such as the heart, brain, or liver) are aging biologically relative to their chronological age. For instance, in June 2024, TruDiagnostic Inc., a US-based epigenetic testing company, launched an organ-specific aging analysis platform developed using the SYMPHONYAge algorithms created at Yale University. The solution leverages high-resolution DNA methylation data to estimate biological age across multiple organ systems, including cardiovascular, metabolic, and neurological profiles, providing deeper insights into differential aging within the body. It is designed to support clinicians, researchers, and longevity-focused healthcare providers in identifying accelerated aging patterns, tracking intervention outcomes, and personalizing anti-aging strategies based on organ-level biological performance.
In April 2026, Infinite Epigenetics Inc., a US-based biotechnology company, acquired Tally Health for an undisclosed amount. Through this acquisition, Infinite Epigenetics aims to expand its direct-to-consumer biological age diagnostics and longevity platform by integrating Tally Health’s at-home epigenetic age testing products, personalized longevity intervention programs, and consumer health engagement capabilities into its broader data-driven diagnostics ecosystem. Tally Health LLC is a US-based consumer biotechnology company specializing in biological age testing using epigenetic age clocks and personalized longevity interventions.
Major companies operating in the epigenetic biological age diagnostic market are Illumina; Zymo Research; TruDiagnostic; Chronomics; Deep Longevity; Elysium Health; MyDNAge; Generation Lab; Nordic Labs; GlycanAge; GenknowMe S.A.; Horvath/UCLA; SiPhox Health; Rhelixa Inc.; MOLEQLAR GmbH; NUGENIS GmbH; epiAge GmbH; Clock Foundation; Nebula Genomics; Cerascreen GmbH; NOVOS Labs.
North America was the largest region in the epigenetic biological age diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epigenetic biological age diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epigenetic biological age diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The epigenetic biological age diagnostic market consists of revenues earned by entities by providing services such as biological age assessment services, aging-risk evaluation, personalized health and longevity analysis, wellness monitoring, and preventive health screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The epigenetic biological age diagnostic market also includes sales of epigenetic analysis panels, laboratory testing reagents, and associated accessories. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The epigenetic biological age diagnostic market research report is one of a series of new reports that provides epigenetic biological age diagnostic market statistics, including epigenetic biological age diagnostic industry global market size, regional shares, competitors with a epigenetic biological age diagnostic market share, detailed epigenetic biological age diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the epigenetic biological age diagnostic industry. This epigenetic biological age diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
The epigenetic biological age diagnostic market size is expected to see rapid growth in the next few years. It will grow to $10.26 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to integration into preventive healthcare systems, expansion of personalized longevity medicine clinics, regulatory approval of standardized epigenetic age clocks, insurance reimbursement for biological age diagnostics, increased clinical trial usage for aging intervention therapies. Major trends in the forecast period include expansion of longevity and wellness clinics adopting biological age diagnostics, increasing regulatory standardization and validation frameworks for epigenetic aging biomarkers, rising integration of biological age testing into insurance and employer wellness programs, growth of direct-to-consumer at-home sample collection and mail-in diagnostic kits, expansion of biobanking and longitudinal cohort studies for aging research.
The increasing demand for personalized medicine is expected to propel the growth of the epigenetic biological age diagnostic market going forward. Personalized medicine refers to a medical approach that tailors disease prevention, diagnosis, and treatment based on an individual’s genetic profile, lifestyle, and environmental factors to improve clinical outcomes. The demand for personalized medicine is rising due to the increasing prevalence of chronic and complex diseases that require targeted therapies and precise diagnostic approaches. Epigenetic biological age diagnostics support personalized medicine by translating DNA methylation-based aging signals into individualized biological age profiles, enabling tailored prevention strategies, treatment selection, and lifestyle interventions for more precise and proactive healthcare. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, a significant increase compared to six approvals in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the epigenetic biological age diagnostic market.
Major companies operating in the epigenetic biological age diagnostic market are focusing on developing innovative platforms such as organ-specific biological age testing algorithms to improve precision in aging assessment, enhance early disease risk prediction, and enable personalized longevity interventions. Organ-specific biological age testing algorithms are computational models that analyze biomarkers such as DNA methylation to estimate how fast individual organs (such as the heart, brain, or liver) are aging biologically relative to their chronological age. For instance, in June 2024, TruDiagnostic Inc., a US-based epigenetic testing company, launched an organ-specific aging analysis platform developed using the SYMPHONYAge algorithms created at Yale University. The solution leverages high-resolution DNA methylation data to estimate biological age across multiple organ systems, including cardiovascular, metabolic, and neurological profiles, providing deeper insights into differential aging within the body. It is designed to support clinicians, researchers, and longevity-focused healthcare providers in identifying accelerated aging patterns, tracking intervention outcomes, and personalizing anti-aging strategies based on organ-level biological performance.
In April 2026, Infinite Epigenetics Inc., a US-based biotechnology company, acquired Tally Health for an undisclosed amount. Through this acquisition, Infinite Epigenetics aims to expand its direct-to-consumer biological age diagnostics and longevity platform by integrating Tally Health’s at-home epigenetic age testing products, personalized longevity intervention programs, and consumer health engagement capabilities into its broader data-driven diagnostics ecosystem. Tally Health LLC is a US-based consumer biotechnology company specializing in biological age testing using epigenetic age clocks and personalized longevity interventions.
Major companies operating in the epigenetic biological age diagnostic market are Illumina; Zymo Research; TruDiagnostic; Chronomics; Deep Longevity; Elysium Health; MyDNAge; Generation Lab; Nordic Labs; GlycanAge; GenknowMe S.A.; Horvath/UCLA; SiPhox Health; Rhelixa Inc.; MOLEQLAR GmbH; NUGENIS GmbH; epiAge GmbH; Clock Foundation; Nebula Genomics; Cerascreen GmbH; NOVOS Labs.
North America was the largest region in the epigenetic biological age diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epigenetic biological age diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epigenetic biological age diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The epigenetic biological age diagnostic market consists of revenues earned by entities by providing services such as biological age assessment services, aging-risk evaluation, personalized health and longevity analysis, wellness monitoring, and preventive health screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The epigenetic biological age diagnostic market also includes sales of epigenetic analysis panels, laboratory testing reagents, and associated accessories. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The epigenetic biological age diagnostic market research report is one of a series of new reports that provides epigenetic biological age diagnostic market statistics, including epigenetic biological age diagnostic industry global market size, regional shares, competitors with a epigenetic biological age diagnostic market share, detailed epigenetic biological age diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the epigenetic biological age diagnostic industry. This epigenetic biological age diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Epigenetic Biological Age Diagnostic Market Characteristics
3. Epigenetic Biological Age Diagnostic Market Supply Chain Analysis
4. Global Epigenetic Biological Age Diagnostic Market Trends And Strategies
5. Epigenetic Biological Age Diagnostic Market Analysis Of End Use Industries
7. Global Epigenetic Biological Age Diagnostic Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
8. Global Epigenetic Biological Age Diagnostic Total Addressable Market (TAM) Analysis for the Market
9. Epigenetic Biological Age Diagnostic Market Segmentation
10. Epigenetic Biological Age Diagnostic Market Regional And Country Analysis
11. Asia-Pacific Epigenetic Biological Age Diagnostic Market
12. China Epigenetic Biological Age Diagnostic Market
13. India Epigenetic Biological Age Diagnostic Market
14. Japan Epigenetic Biological Age Diagnostic Market
15. Australia Epigenetic Biological Age Diagnostic Market
16. Indonesia Epigenetic Biological Age Diagnostic Market
17. South Korea Epigenetic Biological Age Diagnostic Market
18. Taiwan Epigenetic Biological Age Diagnostic Market
19. South East Asia Epigenetic Biological Age Diagnostic Market
20. Western Europe Epigenetic Biological Age Diagnostic Market
21. UK Epigenetic Biological Age Diagnostic Market
22. Germany Epigenetic Biological Age Diagnostic Market
23. France Epigenetic Biological Age Diagnostic Market
24. Italy Epigenetic Biological Age Diagnostic Market
25. Spain Epigenetic Biological Age Diagnostic Market
26. Eastern Europe Epigenetic Biological Age Diagnostic Market
27. Russia Epigenetic Biological Age Diagnostic Market
28. North America Epigenetic Biological Age Diagnostic Market
29. USA Epigenetic Biological Age Diagnostic Market
30. Canada Epigenetic Biological Age Diagnostic Market
31. South America Epigenetic Biological Age Diagnostic Market
32. Brazil Epigenetic Biological Age Diagnostic Market
33. Middle East Epigenetic Biological Age Diagnostic Market
34. Africa Epigenetic Biological Age Diagnostic Market
36. Epigenetic Biological Age Diagnostic Market Competitive Landscape And Company Profiles
37. Epigenetic Biological Age Diagnostic Market Other Major And Innovative Companies
41. Epigenetic Biological Age Diagnostic Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Epigenetic Biological Age Diagnostic Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses epigenetic biological age diagnostic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for epigenetic biological age diagnostic? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The epigenetic biological age diagnostic market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Test Type: Deoxyribonucleic Acid Methylation Clocks; Histone Modification Analysis; Chromatin Remodeling Biomarker Tests; Multi Omics Aging Diagnostics; Other Test Types2) By Technology Platform: Next Generation Sequencing; Mass Spectrometry; Artificial Intelligence Powered Interpretation Software; Microarray
3) By Sample Type: Blood Samples; Saliva Samples; Buccal Swab Samples; Tissue Samples; Other Sample Types
4) By Application Type: Biological Age Estimation; Disease Risk Assessment; Longevity And Wellness Monitoring; Preventive Healthcare; Clinical Research And Drug Development
5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Direct To Consumer Users; Pharmaceutical And Biotech Companies
Subsegments:
1) By Deoxyribonucleic Acid Methylation Clocks: Genome Wide Methylation Clocks; Tissue Specific Methylation Clocks; Cytosine Guanine Rich Region Methylation Clocks; Epigenetic Age Acceleration Clocks2) By Histone Modification Analysis: Histone Acetylation Based Analysis; Histone Methylation Based Analysis; Histone Phosphorylation Based Analysis; Histone Code Mapping
3) By Chromatin Remodeling Biomarker Tests: Nucleosome Positioning Assays; Chromatin Accessibility Assays; Chromatin Looping Interaction Assays; Epigenomic Structure Profiling
4) By Multi Omics Aging Diagnostics: Transcriptomics Based Aging Analysis; Proteomics Based Aging Analysis; Metabolomics Based Aging Analysis; Integrated Multi Layer Aging Models
5) By Other Test Types: Circulating Cell Free Deoxyribonucleic Acid Tests; Senescence Associated Secretory Phenotype Tests; Mitochondrial Epigenetic Function Tests; Telomere Associated Epigenetic Tests
Companies Mentioned: Illumina; Zymo Research; TruDiagnostic; Chronomics; Deep Longevity; Elysium Health; MyDNAge; Generation Lab; Nordic Labs; GlycanAge; GenknowMe S.A.; Horvath/UCLA; SiPhox Health; Rhelixa Inc.; MOLEQLAR GmbH; NUGENIS GmbH; epiAge GmbH; Clock Foundation; Nebula Genomics; Cerascreen GmbH; NOVOS Labs
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
- Illumina
- Zymo Research
- TruDiagnostic
- Chronomics
- Deep Longevity
- Elysium Health
- MyDNAge
- Generation Lab
- Nordic Labs
- GlycanAge
- GenknowMe S.A.
- Horvath/UCLA
- SiPhox Health
- Rhelixa Inc.
- MOLEQLAR GmbH
- NUGENIS GmbH
- epiAge GmbH
- Clock Foundation
- Nebula Genomics
- Cerascreen GmbH
- NOVOS Labs
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | August 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.75 Billion |
| Forecasted Market Value ( USD | $ 10.26 Billion |
| Compound Annual Growth Rate | 15.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
